PGIMER Chandigarh started clinical trial of Sepsivac on asymptomatic Coronavirus patients after the Drug Controller General of India (DCGI) has approved for human trials.
Dr Ram Vishwakarma,coordinator of trial program for use of Sepsivac in COVID-19 treatment said to news agency ANI, "Clinical trial has begun at PGIMER Chandigarh to position immunomodulator Sepsivac as a drug. We are doing another trial on asymptomatic COVID19 patients. It will be given to them as vaccine."
It will be given to them as vaccine so that they don't redevelop infection. So Sepsivac has vaccine as well as therapeutic role, as per Dr. Ram Vishwakarma.
Sepsivac is developed by Cadila Pharmaceuticals and it is the first-in-the-world innovation in Sepsis management and the drug has already received approval from DCGI for immunotherapy treatment in Sepsis or septic shock.
Sepsivac contains mycobacterium w, an immunomodulator which is a non-pathogenic mycobacterium. As a result of the immunomodulator effect, Sepsivac effectively saves more lives in sepsis. Randomized trials in sepsis patients showed 11% absolute reduction and 55.5% relative reduction in mortality.
As per past studies, Sepsivac known to reduce the days on ventilator, incidences of secondary infection and days on vasopressor & reduces the SOFA score.
